This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Blackbaud (BLKB) Up 12.5% Since Last Earnings Report?
by Zacks Equity Research
Blackbaud (BLKB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Blackbaud (BLKB) Climb 37% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 37.1% upside potential for Blackbaud (BLKB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Blackbaud (BLKB) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Blackbaud's (BLKB) first-quarter 2022 revenues benefit from increased recurring revenues and higher transactional volume.
Blackbaud (BLKB) Q1 Earnings Miss Estimates
by Zacks Equity Research
Blackbaud (BLKB) delivered earnings and revenue surprises of -12.31% and 0.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Manhattan Associates (MANH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Manhattan Associates (MANH) delivered earnings and revenue surprises of 33.33% and 6.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Blackbaud (BLKB) Adopts Sustainability Reporting, Boosts ESG Goals
by Zacks Equity Research
Blackbaud (BLKB) became carbon-free for 2021 by using energy efficiently and investing in eco-friendly projects in its quest to build a green future.
Zacks.com featured highlights Ligand Pharmaceuticals, Las Vegas Sands, CoStar Group and Blackbaud
by Zacks Equity Research
Ligand Pharmaceuticals, Las Vegas Sands, CoStar Group and Blackbaud have been highlighted in this Screen of the Week article.
Don't Let These Toxic Stocks Disrupt Your Portfolio
by Rimmi Singhi
Ligand (LGND), Las Vegas Sands (LVS), CoStar (CSGP) and Blackbaud (BLKB) are a few toxic stocks that you should dump to avoid portfolio bleeding.
Blackbaud (BLKB) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Blackbaud (BLKB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blackbaud (BLKB) Now Boasts PayPal and Venmo Payment Options
by Zacks Equity Research
Blackbaud (BLKB) noted that the integrations with PayPal and Venmo will enable social good organizations to create a safe and seamless checkout experience for registration, donations and so on.
Blackbaud (BLKB) Collaborates With Change Donation Platform
by Zacks Equity Research
Blackbaud (BLKB) partners with the Change donation platform to provide companies with "customer-facing giving experiences."
Blackbaud (BLKB) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blackbaud's (BLKB) fourth-quarter 2021 revenues benefit from increases in recurring revenues.
Blackbaud (BLKB) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blackbaud (BLKB) delivered earnings and revenue surprises of 11.94% and 2.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Blackbaud (BLKB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Blackbaud (BLKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include Caesars Entertainment, Blackbaud, Chegg and Sendas Distribuidora
by Zacks Equity Research
Caesars Entertainment, Blackbaud, Chegg and Sendas Distribuidora are included in this blog.
Protect Your Portfolio Health From These 4 Toxic Stocks
by Rimmi Singhi
Usually, toxic stocks are fraught with huge debt loads and are susceptible to external shocks. CZR, BLKB, CHGG and ASAI are some stocks that you should sell now to detoxify your portfolio.
Save Your Portfolio by Getting Rid of These 4 Toxic Stocks
by Rimmi Singhi
Investors who can spot the overpriced stocks and shun them at the right time are the ones likely to make a profit. SGRY, ASAI, BLKB and AZTA are a few toxic stocks that you should disown right away.
Blackbaud (BLKB) Buys EVERFI for $750M: Major Takeaways
by Zacks Equity Research
Blackbaud's (BLKB) EVERFI acquisition expands the company's total addressable market to more than $20 billion
Why Is Blackbaud (BLKB) Down 12.3% Since Last Earnings Report?
by Zacks Equity Research
Blackbaud (BLKB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Blackbaud (BLKB) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Blackbaud (BLKB) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blackbaud's (BLKB) third-quarter 2021 revenues benefit from increases in recurring revenues.
Blackbaud (BLKB) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Blackbaud (BLKB) delivered earnings and revenue surprises of 25.81% and 5.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Blackbaud (BLKB) Q3 Earnings Expected to Decline
by Zacks Equity Research
Blackbaud (BLKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Blackbaud (BLKB) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Blackbaud (BLKB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blackbaud (BLKB) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Blackbaud's (BLKB) second-quarter 2021 revenues are negatively impacted by muted recurring revenue growth.